MedPath

Glucotoxicity and Acute Exercise

Not Applicable
Withdrawn
Conditions
Type 2 Diabetes
Type 1 Diabetes
Registration Number
NCT01771614
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

Experimental hyperglycemia (5 hours) will be induced via a constant- or fluctuating-rate glucose infusion to establish different patterns of glycemia in healthy individuals. The effects of these acute models of hyperglycemia on the adaptations to a single aerobic exercise bout will be tested. Changes in pancreatic endocrine function, insulin sensitivity, endothelial function, and oxidative stress will be measured.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Pancreatic endocrine function0, 6, 7, 9, and 24 hours

The plasma insulin, C-peptide, and glucagon responses to a 0.33 g/kg intravenous glucose tolerance test (IVGTT) will be measured. In each trial, the IVGTT will be performed at T = 0, 6, 7, 9, and 24 hours.

Secondary Outcome Measures
NameTimeMethod
Oxidative stress24 hours

Urine will be collected over the whole 24-hour period of each trial and 8-iso Prostaglandin F3α will be measured.

Endothelial function0, 6, 7, 9, and 24 hours

Blood flow and flow-mediated dilation by Doppler ultrasound will be measured in each trial at T = 0, 6, 7, 9, and 24 hours.

Glucose tolerance0, 6, 7, 9, and 24 hours

Glucose tolerance will be measured during an IVGTT in each trial at T = 0, 6, 7, 9, and 24 hours.

Trial Locations

Locations (1)

University of Birmingham

🇬🇧

Birmingham, West Midlands, United Kingdom

University of Birmingham
🇬🇧Birmingham, West Midlands, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.